Shots:

• The P-III CLL14 trial assessing the efficacy & safety of a combined regimen of Venclyxto/Venclexta + obinutuzumab vs obinutuzumab and chlorambucil in 432 patients with previously untreated CLL
• Results: @median follow-up of 52.4 mos.- PFS rate (74% vs 35.4%) after 1 yr. fixed-duration treatment- 67% reduction in risk of disease progression or death; OS rate (85.4% vs 83.1%)- no new safety signals were identified- improvement in PFS was observed in all clinical & biological risk groups- includes TP53 mutation- 17p deletion & unmutated IGHV status
• Additionally- 26.9% of patients with Venclyxto/Venclexta-based combination still had undetectable MRD compared to 3.2% of patients with obinutuzumab + chlorambucil arm @ 30 mos.

| Ref: Abbvie | Image:abbvie